Bagdade J D
Adv Nephrol Necker Hosp. 1979;8:87-100.
Chronic renal failure results in a variety of metabolic derangements that perturb glucose homeostasis. These may in part result from the fact that the kidney plays a prominent role in the metabolism of insulin as well as a number of other low-molecular-weight peptide hormones that affect carbohydrate metabolism. Specific abnormalities in glucose utilization that appear to be related to alterations in membrane receptors, resulting in increased glucagon sensitivity and decreased insulin action, are a newly recognized factor in intolerance to oral glucose. Glucose production and utilization are both abnormally increased in patients with chronic uremia, and these disturbances are only partially corrected by hemodialysis treatment. The mechanism(s) contributing to these changes is unclear, but seems to involve a combination of humoral and cellular factors. These include some degree of insulin resistance, probably inadequately modulated proteolytic responses to glucagon and parathyroid hormone, and a basic defect in energy production that alters intracellular concentrations of high-energy phosphate-containing nucleotides. It is unclear whether these changes in carbohydrate tolerance pose an increased risk for the premature development of cardiovascular disease in patients with renal failure, as they appear to do in the nonuremic population. The occasional patient with renal failure may develop clinical hypoglycemia when glucose utilization continues in a setting in which the hepatic capacity to produce glucose is reduced, probably as a consequence of altered substrate delivery and/or inhibition of one or more key gluconeogenic enzymes.
慢性肾衰竭会导致多种代谢紊乱,进而扰乱葡萄糖稳态。这些紊乱部分可能是由于肾脏在胰岛素以及其他一些影响碳水化合物代谢的低分子量肽类激素的代谢中发挥着重要作用。葡萄糖利用方面的特定异常似乎与膜受体的改变有关,导致胰高血糖素敏感性增加和胰岛素作用减弱,这是新认识到的口服葡萄糖不耐受的一个因素。慢性尿毒症患者的葡萄糖生成和利用均异常增加,而血液透析治疗只能部分纠正这些紊乱。导致这些变化的机制尚不清楚,但似乎涉及体液和细胞因素的综合作用。这些因素包括一定程度的胰岛素抵抗、可能对胰高血糖素和甲状旁腺激素的蛋白水解反应调节不足,以及能量产生的基本缺陷,后者会改变细胞内含高能磷酸的核苷酸浓度。目前尚不清楚这些碳水化合物耐量的变化是否会像在非尿毒症人群中那样,增加肾衰竭患者心血管疾病过早发生的风险。当肝脏产生葡萄糖的能力降低时,若葡萄糖利用仍在持续,肾衰竭患者偶尔可能会发生临床低血糖,这可能是底物输送改变和/或一种或多种关键糖异生酶受到抑制的结果。